ISRCTN registry — LLMpedia

ISRCTN registry
Name	ISRCTN registry
Type	Clinical trial registry
Launched	2000s
Owner	Public health research infrastructure
Country	United Kingdom
Languages	English

Contents

ISRCTN registry

The ISRCTN registry is an international clinical trial registry that assigns unique numeric identifiers to human research studies and provides searchable trial metadata for researchers, clinicians, patients, and policymakers. It operates within a landscape that includes World Health Organization, European Medicines Agency, National Institutes of Health (United States), Food and Drug Administration and national research funders such as National Institute for Health and Care Research, Wellcome Trust, Bill & Melinda Gates Foundation and major academic sponsors. The registry interacts with large bibliographic and trial databases like PubMed, Cochrane Library, EMBASE, ClinicalTrials.gov, and collaborates with institutions such as University of Oxford, University College London, Imperial College London, King's College London and international bodies including World Health Organization initiatives and the International Committee of Medical Journal Editors.

History

The registry was established amid growing demands for trial transparency following high-profile controversies involving published trials at institutions such as Harvard University, Johns Hopkins University, Vanderbilt University, and pharmaceutical companies including GlaxoSmithKline, Pfizer, AstraZeneca, Novartis and Roche. Early drivers included policy work by World Health Organization, advocacy from groups like AllTrials and editorial mandates from journals represented by the International Committee of Medical Journal Editors and publishers such as Elsevier, Springer Nature, Wiley-Blackwell and BMJ Publishing Group. Over time, interactions with regulators including the European Medicines Agency and national agencies such as the Medicines and Healthcare products Regulatory Agency shaped registry standards. The registry adapted to align with international standards like the WHO Trial Registration Data Set and harmonization efforts alongside ClinicalTrials.gov and regional registries maintained by entities such as Swissmedic, ANSM (France), Federal Institute for Drugs and Medical Devices (Germany) and European Union Clinical Trials Register.

The registry's principal function is to allocate persistent identifiers used by trialists at institutions such as University of Cambridge, University of Edinburgh, University of Manchester, and hospitals like Mayo Clinic, Cleveland Clinic, Guy's and St Thomas' NHS Foundation Trust to ensure public access to trial protocol summaries. It serves sponsors including academic groups, contract research organizations such as IQVIA and Parexel, industry partners like Johnson & Johnson and charitable funders including Cancer Research UK and Wellcome Trust. Scope encompasses interventional and observational human studies in settings ranging from tertiary centers such as Johns Hopkins Hospital and Massachusetts General Hospital to low-resource field sites supported by Médecins Sans Frontières and Bill & Melinda Gates Foundation programs. The registry supports metadata fields recognized by WHO, enabling linkage with data repositories and systematic review services provided by Cochrane, PROSPERO and academic consortia at Harvard School of Public Health and London School of Hygiene & Tropical Medicine.

Trial registration typically requires submission of standardized information about trial design, interventions, outcomes, eligibility, recruitment status and contact details by principal investigators affiliated with institutions such as Stanford University, Yale University, University of California, San Francisco, or corporate sponsors like Merck & Co. and Bristol Myers Squibb. Records are assigned unique numeric identifiers and undergo administrative checks akin to those used by ClinicalTrials.gov and regional registries maintained by organizations such as Japan Pharmaceutical Information Center and Australian New Zealand Clinical Trials Registry. Requirements reflect recommendations from International Committee of Medical Journal Editors and regulatory expectations from agencies including European Medicines Agency and Food and Drug Administration. The process includes options for prospective and retrospective entries, updates for protocol amendments, and fields to record results summaries and links to publications in journals such as The Lancet, New England Journal of Medicine, BMJ, JAMA, and Nature Medicine.

Governance frameworks involve academic and public health stakeholders, with oversight and policy inputs from funding bodies including National Institute for Health and Care Research, Wellcome Trust, Medical Research Council (United Kingdom), and international partners such as World Health Organization. Funding models have combined institutional support, registry fees from commercial sponsors, and collaborations with organizations like Health Data Research UK and publishers including BMJ Publishing Group and Elsevier. Accountability mechanisms reflect norms set by entities such as International Committee of Medical Journal Editors and metrics tracked by bibliometric services like Clarivate and Scopus operated by Elsevier.

The registry promotes public access to trial metadata to facilitate evidence synthesis by systematic reviewers at Cochrane and authors publishing in The BMJ and PLOS Medicine. Metadata enable linkage to trial results repositories, preprint servers like medRxiv and bioRxiv, and data-sharing platforms such as Dryad, Figshare, and controlled-access archives like European Genome-phenome Archive. Transparency practices intersect with policies from World Health Organization, journal requirements from International Committee of Medical Journal Editors, and data-sharing expectations from funders such as Wellcome Trust and Bill & Melinda Gates Foundation. The registry supports public queries used by regulators like European Medicines Agency, journalists at outlets such as BBC and The Guardian, and patient advocacy groups including Cancer Research UK and Alzheimer's Society.

Critiques mirror those directed at other registries: concerns about incomplete outcome reporting noted in analyses by researchers at Duke University and London School of Hygiene & Tropical Medicine, delays between registration and results posting documented in studies from Johns Hopkins University and University of Toronto, and debates over fee structures affecting access for investigators in low- and middle-income countries represented by institutions such as Makerere University and University of Cape Town. Other controversies involve discrepancies between registered protocols and published reports highlighted in work from Cochrane and investigators associated with AllTrials, and ongoing discussions about harmonization with regulators like FDA and transparency advocates including Open Knowledge Foundation and Transparency International.

Category:Clinical trial registries